Results from the SOLARIS trial survey showed that over 92% of patients, 87% of nurses, and 72% of physicians expressed satisfaction with TEV-'749’s initiation regimen, dosing schedule, and overall ...

Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries, announced the presentation of a patient and healthcare professional (HCP) attitudes and experiences survey study, complementing the ...

New data from Israel-based generics giant Teva Pharmaceutical Industries (NYSE: TEVA) show favorable patient and healthcare ...

More than 92% of schizophrenia patients taking Olanzapine LAI in the Phase 3 SOLARIS survey were satisfied or very satisfied with the initiation regimen, dosing schedule and trial medication 1. These ...